ArticleCancer & metabolism2023
Arginase-1 inhibition reduces migration ability and metastatic colonization of colon cancer cells.
Article in Cancer & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Trial
- Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells.Chinese medicine · 2026Article
- Molecular mechanisms and therapies for tumor inhibition through the arginine metabolism pathway.Frontiers in oncology · 2026Review
- Oral L-Arginine treatment attenuatesVirulence · 2025Article
- Intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: a clinical efficacy and multiplex liquid proteomics exploration study.The oncologist · 2025Article
- Suppression of Macrophage Migration and M2 Polarization by an Ethanolic Extract ofJournal of pharmacopuncture · 2025Article
- Immune checkpoint inhibitors: From friend to foe.Toxicology reports · 2025Article
- Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity.Scientific reports · 2025Article
- Arginase Activity Inhibition With Thymoquinone Induces a Hybrid Type of Cell-Death in MDA-MB-231 Cell Line.Journal of biochemical and molecular toxicology · 2025Article
- NOS2/ARG1 axis and immune cell ratios as promising prognostic and predictive biomarkers for Cetuximab combined with chemotherapy in wt-KRAS human colorectal cancer.Frontiers in immunology · 2025Article
- Metabolism of tumor infiltrating T cells.Frontiers in immunology · 2025Review
- Serum Metabolites as Diagnostic Biomarkers in Patients with Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Engineered microparticles modulate arginine metabolism to repolarize tumor-associated macrophages for refractory colorectal cancer treatment.Journal of translational medicine · 2024Article
- From the Inside Out: Exposing the Roles of Urea Cycle Enzymes in Tumors and Their Micro and Macro Environments.Cold Spring Harbor perspectives in medicine · 2024Review
- Recent advances in DDAH1 inhibitor design and discovery: insights from structure-activity relationships and X-ray crystal structures.RSC advances · 2024Review
- Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma.Frontiers in immunology · 2024Article
- Comprehensive analysis of CXCL14 uncovers its role during liver metastasis in colon cancer.BMC gastroenterology · 2023Article
- Genetics of enzymatic dysfunctions in metabolic disorders and cancer.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArginase-1 (ARG1), a urea cycle-related enzyme, catalyzes the hydrolysis of arginine to urea and ornithine, which regulates the proliferation, differentiation, and function of various cells. However, it is unclear whether ARG1 controls the progression and malignant alterations of colon cancer.
methodsWe established metastatic colonization mouse model and ARG1 overexpressing murine colon cancer CT26 cells to investigate whether activation of ARG1 was related to malignancy of colon cancer cells in vivo. Living cell numbers and migration ability of CT26 cells were evaluated in the presence of ARG inhibitor in vitro.
resultsInhibition of arginase activity significantly suppressed the proliferation and migration ability of CT26 murine colon cancer cells in vitro. Overexpression of ARG1 in CT26 cells reduced intracellular L-arginine levels, enhanced cell migration, and promoted epithelial-mesenchymal transition. Metastatic colonization of CT26 cells in lung and liver tissues was significantly augmented by ARG1 overexpression in vivo. ARG1 gene expression was higher in the tumor tissues of liver metastasis than those of primary tumor, and arginase inhibition suppressed the migration ability of HCT116 human colon cancer cells.
conclusionActivation of ARG1 is related to the migration ability and metastatic colonization of colon cancer cells, and blockade of this process may be a novel strategy for controlling cancer malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.